DURECT (DRRX) 10-Q 8 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'DRRX	'
Entity Registrant Name	'DURECT CORP	'
Entity Central Index Key	'0001082038	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	111,596,607

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$18,674	$7,836
Short-term investments	14,299	12,753
Accounts receivable (net of allowances of $190 at June 30, 2014 and $144 at December 31, 2013)	2,276	2,349
Inventories	4,554	3,502
Prepaid expenses and other current assets	751	1,888
Total current assets	40,554	28,328
Property and equipment (net of accumulated depreciation of $20,448 and $20,488 at June 30, 2014 and December 31, 2013, respectively)	1,826	1,985
Goodwill	6,399	6,399
Intangible assets, net	9	18
Long-term investments	4,012	3,352
Long-term restricted investments	350	450
Other long-term assets	288	288
Total assets	53,438	40,820
Current liabilities:	'	'
Accounts payable	666	736
Accrued liabilities	4,687	5,865
Contract research liabilities	169	329
Deferred revenue, current portion	255	255
Total current liabilities	5,777	7,185
Deferred revenue, non-current portion	1,169	1,296
Long-term debt, net	19,786	0
Other long-term liabilities	1,641	1,618
Commitments and contingencies	'	'
Stockholders' equity:	'	'
Preferred stock	0	0
Common stock	11	11
Additional paid-in capital	394,925	391,504
Accumulated other comprehensive income	2	1
Accumulated deficit	-369,873	-360,795
Stockholders' equity	25,065	30,721
Total liabilities and stockholders' equity	$53,438	$40,820

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Allowances for accounts receivable	$190	$144
Accumulated depreciation on property and equipment	$20,448	$20,488

Condensed_Statements_of_Compre

Condensed Statements of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Collaborative research and development and other revenue (see Note 2)	$1,735	$905	$5,247	$1,818
Product revenue, net	2,846	3,013	5,627	6,253
Total revenues	4,581	3,918	10,874	8,071
Operating expenses:	'	'	'	'
Cost of product revenues	1,091	1,032	2,154	2,690
Research and development	6,088	4,833	11,557	9,622
Selling, general and administrative	2,850	3,210	6,213	6,111
Total operating expenses	10,029	9,075	19,924	18,423
Loss from operations	-5,448	-5,157	-9,050	-10,352
Other income (expense):	'	'	'	'
Interest and other income (expenses), net	3	13	6	27
Interest expense	-33	-1	-34	-3
Net other income	-30	12	-28	24
Net loss	-5,478	-5,145	-9,078	-10,328
Net loss per share	'	'	'	'
Basic	($0.05)	($0.05)	($0.08)	($0.10)
Diluted	($0.05)	($0.05)	($0.08)	($0.10)
Weighted-average shares used in computing net loss per share	'	'	'	'
Basic	110,570	101,954	110,519	101,918
Diluted	110,570	101,954	110,519	101,918
Total comprehensive loss	($5,481)	($5,146)	($9,077)	($10,331)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities	'	'
Net loss	($9,078)	($10,328)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	310	512
Stock-based compensation	1,501	1,796
Changes in assets and liabilities:	'	'
Accounts receivable	73	154
Inventories	-1,055	248
Prepaid expenses and other assets	1,137	814
Accounts payable	-70	-1,014
Accrued and other liabilities	524	979
Contract research liabilities	-160	-343
Deferred revenue	-127	-463
Total adjustments	2,133	2,683
Net cash used in operating activities	-6,945	-7,645
Cash flows from investing activities	'	'
Purchases of property and equipment	-91	-54
Purchases of available-for-sale securities	-10,600	-6,790
Proceeds from maturities of available-for-sale securities	8,495	11,200
Net cash (used in) provided by investing activities	-2,196	4,356
Cash flows from financing activities	'	'
Payments on equipment financing obligations	-7	-4
Net proceeds from issuance of long-term debt	19,786	0
Net proceeds from issuances of common stock	200	87
Net cash provided by financing activities	19,979	83
Net increase (decrease) in cash and cash equivalents	10,838	-3,206
Cash and cash equivalents, beginning of the period	7,836	11,195
Cash and cash equivalents, end of the period	$18,674	$7,989

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 1. Summary of Significant Accounting Policies (TO ADD RECENT ACCOUNTING PRONOUNCEMENTS)
	Nature of Operations
	DURECT Corporation (the Company) was incorporated in the state of Delaware on February 6, 1998. The Company is a pharmaceutical company developing therapies based on its proprietary drug formulations and delivery platform technologies. The Company has several products under development by itself and with third party collaborators. The Company also manufactures and sells osmotic pumps used in laboratory research, and designs, develops and manufactures a wide range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. In addition, the Company conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies.
	Basis of Presentation
	The accompanying unaudited financial statements include the accounts of the Company. These financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and therefore do not include all the information and footnotes necessary for a complete presentation of the Company’s results of operations, financial position and cash flows in conformity with U.S. generally accepted accounting principles (U.S. GAAP). The unaudited financial statements reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position at June 30, 2014, the operating results and comprehensive loss for the three and six months ended June 30, 2014 and 2013, and cash flows for the six months ended June 30, 2014 and 2013. The balance sheet as of December 31, 2013 has been derived from audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements and notes should be read in conjunction with the Company’s audited financial statements and notes thereto, included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2013 filed with the SEC.
	The results of operations for the interim periods presented are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year.
	Inventories
	Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company’s inventories consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Raw materials	$	2,289		$	1,404
	Work in process		1,070			1,063
	Finished goods		1,195			1,035
	Total inventories	$	4,554		$	3,502
	Revenue Recognition
	Revenue from the sale of products is recognized when there is persuasive evidence that an arrangement exists, the product is shipped and title transfers to customers, provided no continuing obligation on the Company’s part exists, the price is fixed or determinable and the collectability of the amounts owed is reasonably assured. The Company enters into license and collaboration agreements under which it may receive upfront license fees, research funding and contingent milestone payments and royalties. The Company’s deliverables under these arrangements typically consist of granting licenses to intellectual property rights and providing research and development services. The accounting standards contain a presumption that separate contracts entered into at or near the same time with the same entity or related parties were negotiated as a package and should be evaluated as a single agreement.
	Revenue on cost-plus-fee contracts, such as under contracts to perform research and development for others, is recognized as the related services are rendered as determined by the extent of reimbursable costs incurred plus estimated fees thereon.
	Comprehensive Income (Loss)
	Components of other comprehensive income (loss) are comprised entirely of unrealized gains and losses on the Company’s available-for-sale securities for all periods presented and are included in total comprehensive income (loss) as follows (in thousands).
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Net loss	$	(5,478	)	$	(5,145	)	$	(9,078	)	$	(10,328	)
	Net change in unrealized gain on available-for-sale investments, net of tax		(3	)		(1	)		1			(3	)
	Comprehensive loss	$	(5,481	)	$	(5,146	)	$	(9,077	)	$	(10,331	)
	The tax effect of the changes in accumulated other comprehensive income (loss) was immaterial for the periods presented. Accumulated other comprehensive income as of June 30, 2014 and December 31, 2013 is entirely comprised of net unrealized gains on available-for-sale securities.
	Net Income (Loss) Per Share
	Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed using the weighted-average number of common shares outstanding and common stock equivalents (i.e., options to purchase common stock) outstanding during the period, if dilutive, using the treasury stock method for options and warrants.
	Options to purchase approximately 20.2 million and 19.5 million shares of common stock were excluded from the denominator in the calculation of diluted net loss per share for the three and six months ended June 30, 2014, respectively, as the effect would be anti-dilutive. Options to purchase approximately 22.2 million and 21.6 million shares of common stock were excluded from the denominator in the calculation of diluted net loss per share for the three and six months ended June 30, 2013, respectively, as the effect would be anti-dilutive.
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in ASC 606, Revenue Recognition – Revenue from Contracts with Customers, which amends the guidance in former ASC 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The guidance provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). The standard will be effective for public entities for annual and interim periods beginning after December 15, 2016. The Company is currently evaluating the impact of the provisions of ASC 606.

Strategic_Agreements

Strategic Agreements	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Strategic Agreements	'
	Note 2. Strategic Agreements
	The collaborative research and development and other revenues associated with the Company’s major third-party collaborators are as follows (in thousands):
			Three months ended				Six months ended
			June 30,				June 30,
			2014		2013		2014		2013
	Collaborator
	Zogenix, Inc. (Zogenix) (1)		$	1,383	$	247	$	2,164	$	499
	Pain Therapeutics, Inc. (Pain Therapeutics)			246		—		697		1
	Pfizer Inc. (Pfizer)			73		—		87		13
	Impax Laboratories, Inc. (Impax) (2)			—		—		2,090		—
	Others			33		658		209		1,305
	Total collaborative research and development and other revenue		$	1,735	$	905	$	5,247	$	1,818
	-1	Amounts related to ratable recognition of upfront fees were $64,000 and $127,000 for the three and six months ended June 30, 2014, respectively, compared to $64,000 and $113,000 for the corresponding periods in 2013.
	-2	Amounts related to recognition of upfront fees were zero and $2.0 million for three months and six months ended June 30, 2014, respectively; the Company and Impax signed a license agreement effective January 3, 2014.
	Agreement with Impax Laboratories, Inc.
	On January 3, 2014, the Company and Impax Laboratories, Inc. (Impax) entered into a definitive agreement (the Impax Agreement). Pursuant to the Agreement, the Company has granted Impax an exclusive worldwide license to the Company’s proprietary TRANSDUR transdermal delivery technology and other intellectual property to develop and commercialize ELADUR, the Company’s investigational transdermal bupivacaine patch for the treatment of pain associated with post-herpetic neuralgia (PHN), in addition to selling certain assets and rights in and related to the product. Impax will control and fund the development and commercialization programs, and the parties will establish a joint management committee to oversee, review and coordinate the development and commercialization activities of the parties under the Impax Agreement. Impax will reimburse the Company for certain future research and development it may be requested to conduct on the product.
	In connection with the Agreement, Impax paid a non-refundable upfront fee to the Company of $2.0 million in January 2014. The Company’s technology transfer activities were considered integral to utilizing the licensed intellectual property and, accordingly, the deliverables were accounted for as a single unit of accounting. The $2.0 million upfront fee was recognized as collaborative research and development revenue in the first quarter of 2014 when the license to the intellectual property right was delivered and the technology transfer with respect to this product candidate was completed. Impax agreed to make contingent cash payments to the Company of up to $61.0 million payable based upon the achievement of predefined milestones, of which $31.0 million are development-based milestones and $30.0 million are sales-based milestones (none of which has been achieved as of June 30, 2014). Since the milestones are expected to be achieved at a point in time when there are no performance obligations or remaining deliverables of the Company, the milestones are expected to be recognized in full upon achievement. Upon the first commercialization of ELADUR by Impax, the Company would also receive a tiered mid single-digit to low double-digit royalty on annual net product sales determined on a country-by-country basis. Impax is also required to pay to the Company a percentage of fees received in connection with any sublicense of the licensed rights. Impax may terminate the Impax Agreement without cause at any time upon prior written notice, and either party may terminate the Impax Agreement upon certain circumstances including written notice of a material uncured breach.
	The following table provides a summary of collaborative research and development revenue recognized under the Impax Agreement (in thousands). The cumulative aggregate payments received by the Company as of June 30, 2014 were $2.1 million under the agreement.
			Three months ended				Six months ended
			June 30,				June 30,
			2014		2013		2014		2013
	Ratable recognition of upfront payment		$	—	$	—	$	2,000	$	—
	Research and development expenses reimbursable by Impax			—		—		90		—
	Total collaborative research and development revenue		$	—	$	—	$	2,090	$	—
	Agreement with Pain Therapeutics, Inc.
	In December 2002, the Company entered into an exclusive agreement with Pain Therapeutics, Inc. (Pain Therapeutics) to develop and commercialize on a worldwide basis REMOXY and other oral sustained release, abuse deterrent opioid products incorporating four specified opioid drugs, using the ORADUR technology. Total collaborative research and development revenue recognized under the agreements with Pain Therapeutics was $246,000 and $697,000 for the three and six months ended June 30, 2013, respectively, compared with zero and $1,000 for the corresponding periods in 2013. The cumulative aggregate payments received by the Company from Pain Therapeutics as of June 30, 2014 were $35.5 million under this agreement.
	Under the terms of this agreement, Pain Therapeutics paid the Company an upfront license fee of $1.0 million, with the potential for an additional $9.3 million in performance milestone payments based on the successful development and approval of the four ORADUR-based opioids. Of these potential milestones, $9.3 million are development-based milestones (of which $1.7 million have been achieved as of June 30, 2014). There are no sales-based milestones under the agreement.
	In March 2009, King Pharmaceuticals (King) assumed the responsibility for further development of REMOXY from Pain Therapeutics. As a result of this change, the Company continues to perform REMOXY-related activities in accordance with the terms and conditions set forth in the license agreement between the Company and Pain Therapeutics. King was substituted in lieu of Pain Therapeutics with respect to interactions with the Company in its performance of those activities including the obligation to pay the Company with respect to all REMOXY-related costs incurred by the Company. In February 2011, Pfizer acquired King and thereby assumed the rights and obligations of King with respect to REMOXY; accordingly, amounts attributed to King are now shown as Pfizer figures.
	Total collaborative research and development revenue recognized for REMOXY-related work performed by the Company for Pfizer was $73,000 and $87,000 for the three and six months ended June 30, 2014, respectively, compared with zero and $13,000 for the corresponding periods in 2013. Prior to March 2009, the Company recognized collaborative research and development revenue for REMOXY-related work under the agreements with Pain Therapeutics. The cumulative aggregate payments received by the Company from Pfizer as of June 30, 2014 were $7.1 million under this agreement.
	Long Term Supply Agreement with King (now Pfizer)
	In August 2009, the Company signed an exclusive long term excipient supply agreement with respect to REMOXY with King. In February 2011, Pfizer acquired King and thereby assumed the rights and obligations of King with respect to this long term supply agreement. This agreement stipulates the terms and conditions under which the Company will supply to King, based on the Company’s manufacturing cost plus a specified percentage mark-up, two key excipients used in the manufacture of REMOXY.
	Total revenues recognized related to these excipients were zero for both the three and six months ended June 30, 2014, compared with zero and $273,000 for the corresponding periods in 2013. The associated costs of goods sold were zero for both the three and six months ended June 30, 2014, compared to zero and $219,000 for the corresponding periods in 2013.
	Agreement with Zogenix, Inc.
	On July 11, 2011, the Company and Zogenix, Inc. (Zogenix) entered into a Development and License Agreement (the Zogenix Agreement). The Company and Zogenix had previously been working together under a feasibility agreement pursuant to which the Company’s research and development costs were reimbursed by Zogenix. Under the Zogenix Agreement, Zogenix will be responsible for the clinical development and commercialization of a proprietary, long-acting injectable formulation of risperidone using the Company’s SABER controlled-release formulation technology in combination with Zogenix’s DosePro® needle-free, subcutaneous drug delivery system. DURECT will be responsible for non-clinical, formulation and CMC development activities. The Company will be reimbursed by Zogenix for its research and development efforts on the product.
	Zogenix paid a non-refundable upfront fee to the Company of $2.25 million in July 2011. The Company’s research and development services are considered integral to utilizing the licensed intellectual property and, accordingly, the deliverables are accounted for as a single unit of accounting. The $2.25 million upfront fee will be recognized as collaborative research and development revenue ratably over the term of the Company’s continuing research and development involvement with Zogenix with respect to this product candidate. Zogenix is obligated to pay the Company up to $103 million in total future milestone payments with respect to the product subject to and upon the achievement of various developments, regulatory and sales milestones. Of these potential milestones, $28 million are development-based milestones (none of which has been achieved as of June 30, 2014), and $75 million are sales-based milestones (none of which has been achieved as of June 30, 2014). Zogenix is also required to pay a mid single-digit to low double-digit percentage patent royalty on annual net sales of the product determined on a jurisdiction-by-jurisdiction basis. The patent royalty term is equal to the later of the expiration of all DURECT technology patents or joint patent rights in a particular jurisdiction, the expiration of marketing exclusivity rights in such jurisdiction, or 15 years from first commercial sale in such jurisdiction. After the patent royalty term, Zogenix will continue to pay royalties on annual net sales of the product at a reduced rate for so long as Zogenix continues to sell the product in the jurisdiction. Zogenix is also required to pay to the Company a tiered percentage of fees received in connection with any sublicense of the licensed rights.
	The Company granted to Zogenix an exclusive worldwide license, with sub-license rights, to the Company’s intellectual property rights related to the Company’s proprietary polymeric and non-polymeric controlled-release formulation technology to make and have made, use, offer for sale, sell and import risperidone products, where risperidone is the sole active agent, for administration by injection in the treatment of schizophrenia, bipolar disorder or other psychiatric related disorders in humans. The Company retains the right to supply Zogenix’s Phase III clinical trial and commercial product requirements on the terms set forth in the Zogenix Agreement.
	The Company retains the right to terminate the Zogenix Agreement with respect to specific countries if Zogenix fails to advance the development of the product in such country, either directly or through a sublicensee. In addition, either party may terminate the Zogenix Agreement upon insolvency or bankruptcy of the other party, upon written notice of a material uncured breach or if the other party takes any act impairing such other party’s relevant intellectual property rights. Zogenix may terminate the Zogenix Agreement upon written notice if during the development or commercialization of the product, the product becomes subject to one or more serious adverse drug experiences or if either party receives notice from a regulatory authority, independent review committee, data safety monitory board or other similar body alleging significant concern regarding a patient safety issue. Zogenix may also terminate the Zogenix Agreement with or without cause, at any time upon prior written notice.
	The following table provides a summary of collaborative research and development revenue recognized under the agreements with Zogenix (in thousands). The cumulative aggregate payments received by the Company as of June 30, 2014 were $12.0 million under these agreements.
			Three months ended				Six months ended
			June 30,				June 30,
			2014		2013		2014		2013
	Ratable recognition of upfront payment		$	64	$	64	$	127	$	113
	Research and development expenses reimbursable by Zogenix			1,319		183		2,037		386
	Total collaborative research and development revenue		$	1,383	$	247	$	2,164	$	499

Financial_Instruments

Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial Instruments	'
	Note 3. Financial Instruments
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company’s valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company follows a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value. These levels of inputs are the following:
		•		Level 1—Quoted prices in active markets for identical assets or liabilities.
		•		Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s financial instruments are valued using quoted prices in active markets or based upon other observable inputs. Money market funds are classified as Level 1 financial assets. Certificates of deposit, commercial paper, corporate debt securities, and U.S. Government agency securities are classified as Level 2 financial assets. The fair value of the Level 2 assets is estimated using pricing models using current observable market information for similar securities. The Company’s Level 2 investments include U.S. government-backed securities and corporate securities that are valued based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. The fair value of the Company’s commercial paper is based upon the time to maturity and discounted using the three-month treasury bill rate. The average remaining maturity of the Company’s Level 2 investments as of June 30, 2014 is less than twelve months and these investments are rated by S&P and Moody’s at AAA or AA- for securities and A1 or P1 for commercial paper.
	The following is a summary of available-for-sale securities as of June 30, 2014 and December 31, 2013 (in thousands):
			June 30, 2014
			Amortized		Unrealized		Unrealized			Estimated
			Cost		Gain		Loss			Fair
										Value
	Money market funds		$	17,284	$	—	$	—		$	17,284
	Certificates of deposit			350		—		—			350
	Commercial paper			500		—		—			500
	Corporate debt			4,840		1		(1	)		4,840
	U.S. Government agencies			13,169		3		(1	)		13,171
			$	36,143	$	4	$	(2	)	$	36,145
	Reported as:
	Cash and cash equivalents		$	17,484	$	—	$	—		$	17,484
	Short-term investments			14,298		2		(1	)		14,299
	Long-term investments			4,011		2		(1	)		4,012
	Long-term restricted investments			350		—		—			350
			$	36,143	$	4	$	(2	)	$	36,145
			December 31, 2013
			Amortized		Unrealized		Unrealized			Estimated
			Cost		Gain		Loss			Fair
										Value
	Money market funds		$	34	$	—	$	—		$	34
	Certificates of deposit			450		—		—			450
	Commercial paper			1,249		—		—			1,249
	Corporate debt			3,257		1		—			3,258
	U.S. Government agencies			16,898		1		(1	)		16,898
			$	21,888	$	2	$	(1	)	$	21,889
	Reported as:
	Cash and cash equivalents		$	5,334	$	—	$	—		$	5,334
	Short-term investments			12,752		2		(1	)		12,753
	Long-term investments			3,352		—		—			3,352
	Long-term restricted investments			450		—		—			450
			$	21,888	$	2	$	(1	)	$	21,889
	The following is a summary of the cost and estimated fair value of available-for-sale securities at June 30, 2014, by contractual maturity (in thousands):
			June 30, 2014
			Amortized		Estimated
			Cost		Fair
					Value
	Mature in one year or less		$	14,848	$	14,849
	Mature after one year through five years			4,011		4,012
			$	18,859	$	18,861
	There were no securities that have had an unrealized loss for more than 12 months as of June 30, 2014.
	As of June 30, 2014, unrealized losses on available-for-sale investments are not attributed to credit risk and are considered to be temporary. The Company believes that it is more-likely-than-not that investments in an unrealized loss position will be held until maturity or the recovery of the cost basis of the investment. To date, the Company has not recorded any impairment charges on marketable securities related to other-than-temporary declines in market value.

StockBased_Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Stock-Based Compensation	'
	Note 4. Stock-Based Compensation
	As of June 30, 2014, the Company has three stock-based compensation plans. The stock-based compensation cost that has been included in the statements of comprehensive loss is shown as below (in thousands):
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Cost of product revenues	$	38		$	43		$	75		$	92
	Research and development		424			501			839			1,071
	Selling, general and administrative		313			307			587			633
	Total stock-based compensation	$	775		$	851		$	1,501		$	1,796
	As of June 30, 2014 and December 31, 2013, $14,000 and $13,000, respectively, of stock-based compensation cost was capitalized in inventory on the Company’s balance sheets.
	The Company uses the Black-Scholes option pricing model to value its stock options. The expected life computation is based on historical exercise patterns and post-vesting termination behavior. The Company considered its historical volatility in developing its estimate of expected volatility.
	The Company used the following assumptions to estimate the fair value of stock options granted (including fully vested options issued in January 2014 and February 2013) and shares purchased under its employee stock purchase plan for the three and six months ended June 30, 2014 and 2013:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock options
	Risk-free rate		2.1-2.5	%		1.0-2.5	%		2.0-2.8	%		0.8-2.5	%
	Expected dividend yield		—			—			—			—
	Expected life of option (in years)		6.5-10.0			6.5-9.8			6.5-10.0			5.3-9.8
	Volatility		80-83	%		81-83	%		77-84	%		77-83	%
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Employee Stock Purchase Plan
	Risk-free rate		0.1	%		0.1	%		0.1	%		0.1-0.2	%
	Expected dividend yield		—			—			—			—
	Expected life of option (in years)		0.5			0.5			0.5			0.5
	Volatility		60	%		64	%		60-81	%		64-69	%

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Note 5. Long-Term Debt
	On June 26, 2014, the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC, pursuant to which Oxford provided a $20 million secured single-draw term loan to the Company with a maturity date of July 1, 2018. The term loan was fully drawn at close and the proceeds are to be used for working capital and general business requirements. The term loan repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears starting on February 1, 2016 and continuing through the maturity date. The Loan Agreement provides for a 7.95% interest rate on the term loan, a $150,000 facility fee that was paid at closing and an additional payment equal to 8% of the principal amount of the term loan, which is due when the term loan becomes due or upon the prepayment of the facility. If the Company elects to prepay the loan, there is also a prepayment fee between 1% and 3% of the principal amount of the term loan depending on the timing and circumstances of prepayment.
	In connection with the term loan, the Company received proceeds of $19.8 million, net of debt offering/issuance costs. The debt offering/issuance costs have been recorded as debt discount on the Company’s balance sheet which together with the final $1.6 million payment and fixed interest rate payments will be amortized to interest expense throughout the life of the term loan using the effective interest rate method.
	The term loan is secured by substantially all of the assets of the Company, except that the collateral does not include any intellectual property (including licensing, collaboration and similar agreements relating thereto), and certain other excluded assets. The Loan Agreement contains customary representations, warranties and covenants by the Company, which covenants limit the Company’s ability to convey, sell, lease, transfer, assign or otherwise dispose of certain assets of the Company; engage in any business other than the businesses currently engaged in by the Company or reasonably related thereto; liquidate or dissolve; make certain management changes; undergo certain change of control events; create, incur, assume, or be liable with respect to certain indebtedness; grant certain liens; pay dividends and make certain other restricted payments; make certain investments; and make payments on any subordinated debt.
	The Loan Agreement also contains customary indemnification obligations and customary events of default, including, among other things, our failure to fulfill certain obligations of the Company under the Loan Agreement and the occurrence of a material adverse change which is defined as a material adverse change in the Company’s business, operations, or condition (financial or otherwise), a material impairment of the prospect of repayment of any portion of the loan, or a material impairment in the perfection or priority of lender’s lien in the collateral or in the value of such collateral. In the event of default by the Company under the Loan Agreement, the lender would be entitled to exercise its remedies thereunder, including the right to accelerate the debt, upon which the Company may be required to repay all amounts then outstanding under the Loan Agreement, which could harm the Company’s financial condition.
	As of June 30, 2014, the Company was in compliance with all material covenants under the Loan Agreement and there had been no material adverse change.
	Future maturities and interest payments under the term loan as of June 30, 2014, are as follows (in thousands):
	Six months ended December 31, 2014	$	795
	2015		1,590
	2016		8,848
	2017		8,848
	2018		6,023
	Total minimum payments		26,104
	Less amount representing interest		-6,104
	Gross balance of long-term debt		20,000
	Less unamortized debt discount		-214
	Carrying value of long-term debt		19,786
	Less current portion of long-term debt		—
	Long-term debt, less current portion and unamortized debt discount	$	19,786
	Interest expense, including amortization of the debt discount, related to the long-term debt was $31,000 for both three and six months ended June 30, 2014. Accrued interest, which is included in other long-term liabilities, was approximately $8,000 as of June 30, 2014.

Subsequent_Event

Subsequent Event	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Event	'
	Note 6. Subsequent Event
	In December 2013, the Company filed a new shelf registration statement on Form S-3 with the SEC, which upon being declared effective in January 2014, allows for the offer of up to $100.9 million of securities from time to time in one or more public offerings of common stock. In addition, the Company entered into a Controlled Equity Offering SM sales agreement with Cantor Fitzgerald & Co. (Cantor Fitzgerald) under which the Company may sell, subject to certain limitations, up to $25 million of common stock through Cantor Fitzgerald, acting as agent.
	During July 2014, the Company raised net proceeds (net of commission) of approximately $1.6 million from the sale of 967,057 shares of its common stock at a weighted average price of $1.76 per share in the open market through its agreement with Cantor Fitzgerald.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Nature of Operations	'
	Nature of Operations
	DURECT Corporation (the Company) was incorporated in the state of Delaware on February 6, 1998. The Company is a pharmaceutical company developing therapies based on its proprietary drug formulations and delivery platform technologies. The Company has several products under development by itself and with third party collaborators. The Company also manufactures and sells osmotic pumps used in laboratory research, and designs, develops and manufactures a wide range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products. In addition, the Company conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies.
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited financial statements include the accounts of the Company. These financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC), and therefore do not include all the information and footnotes necessary for a complete presentation of the Company’s results of operations, financial position and cash flows in conformity with U.S. generally accepted accounting principles (U.S. GAAP). The unaudited financial statements reflect all adjustments (consisting only of normal recurring adjustments) which are, in the opinion of management, necessary for a fair presentation of the financial position at June 30, 2014, the operating results and comprehensive loss for the three and six months ended June 30, 2014 and 2013, and cash flows for the six months ended June 30, 2014 and 2013. The balance sheet as of December 31, 2013 has been derived from audited financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements and notes should be read in conjunction with the Company’s audited financial statements and notes thereto, included in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2013 filed with the SEC.
	The results of operations for the interim periods presented are not necessarily indicative of results that may be expected for any other interim period or for the full fiscal year.
Inventories	'
	Inventories
	Inventories are stated at the lower of cost or market, with cost determined on a first-in, first-out basis. The Company’s inventories consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Raw materials	$	2,289		$	1,404
	Work in process		1,070			1,063
	Finished goods		1,195			1,035
	Total inventories	$	4,554		$	3,502
Revenue Recognition	'
	Revenue Recognition
	Revenue from the sale of products is recognized when there is persuasive evidence that an arrangement exists, the product is shipped and title transfers to customers, provided no continuing obligation on the Company’s part exists, the price is fixed or determinable and the collectability of the amounts owed is reasonably assured. The Company enters into license and collaboration agreements under which it may receive upfront license fees, research funding and contingent milestone payments and royalties. The Company’s deliverables under these arrangements typically consist of granting licenses to intellectual property rights and providing research and development services. The accounting standards contain a presumption that separate contracts entered into at or near the same time with the same entity or related parties were negotiated as a package and should be evaluated as a single agreement.
	Revenue on cost-plus-fee contracts, such as under contracts to perform research and development for others, is recognized as the related services are rendered as determined by the extent of reimbursable costs incurred plus estimated fees thereon.
Comprehensive Income (Loss)	'
	Comprehensive Income (Loss)
	Components of other comprehensive income (loss) are comprised entirely of unrealized gains and losses on the Company’s available-for-sale securities for all periods presented and are included in total comprehensive income (loss) as follows (in thousands).
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Net loss	$	(5,478	)	$	(5,145	)	$	(9,078	)	$	(10,328	)
	Net change in unrealized gain on available-for-sale investments, net of tax		(3	)		(1	)		1			(3	)
	Comprehensive loss	$	(5,481	)	$	(5,146	)	$	(9,077	)	$	(10,331	)
	The tax effect of the changes in accumulated other comprehensive income (loss) was immaterial for the periods presented. Accumulated other comprehensive income as of June 30, 2014 and December 31, 2013 is entirely comprised of net unrealized gains on available-for-sale securities.
Net Income (Loss) Per Share	'
	Net Income (Loss) Per Share
	Basic net income (loss) per share is calculated by dividing the net income (loss) by the weighted-average number of common shares outstanding. Diluted net income (loss) per share is computed using the weighted-average number of common shares outstanding and common stock equivalents (i.e., options to purchase common stock) outstanding during the period, if dilutive, using the treasury stock method for options and warrants.
	Options to purchase approximately 20.2 million and 19.5 million shares of common stock were excluded from the denominator in the calculation of diluted net loss per share for the three and six months ended June 30, 2014, respectively, as the effect would be anti-dilutive. Options to purchase approximately 22.2 million and 21.6 million shares of common stock were excluded from the denominator in the calculation of diluted net loss per share for the three and six months ended June 30, 2013, respectively, as the effect would be anti-dilutive.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In May 2014, the Financial Accounting Standards Board (FASB) issued guidance codified in ASC 606, Revenue Recognition – Revenue from Contracts with Customers, which amends the guidance in former ASC 605, Revenue Recognition. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The guidance provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). The standard will be effective for public entities for annual and interim periods beginning after December 15, 2016. The Company is currently evaluating the impact of the provisions of ASC 606.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Components of Inventories	'
	The Company’s inventories consisted of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Raw materials	$	2,289		$	1,404
	Work in process		1,070			1,063
	Finished goods		1,195			1,035
	Total inventories	$	4,554		$	3,502
Summary of Components of Comprehensive Income (Loss)	'
	Components of other comprehensive income (loss) are comprised entirely of unrealized gains and losses on the Company’s available-for-sale securities for all periods presented and are included in total comprehensive income (loss) as follows (in thousands).
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Net loss	$	(5,478	)	$	(5,145	)	$	(9,078	)	$	(10,328	)
	Net change in unrealized gain on available-for-sale investments, net of tax		(3	)		(1	)		1			(3	)
	Comprehensive loss	$	(5,481	)	$	(5,146	)	$	(9,077	)	$	(10,331	)

Strategic_Agreements_Tables

Strategic Agreements (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Collaborative Research and Development and Other Revenues Associated with Company's Major Third-Party Collaborators	'
	The collaborative research and development and other revenues associated with the Company’s major third-party collaborators are as follows (in thousands):
			Three months ended				Six months ended
			June 30,				June 30,
			2014		2013		2014		2013
	Collaborator
	Zogenix, Inc. (Zogenix) (1)		$	1,383	$	247	$	2,164	$	499
	Pain Therapeutics, Inc. (Pain Therapeutics)			246		—		697		1
	Pfizer Inc. (Pfizer)			73		—		87		13
	Impax Laboratories, Inc. (Impax) (2)			—		—		2,090		—
	Others			33		658		209		1,305
	Total collaborative research and development and other revenue		$	1,735	$	905	$	5,247	$	1,818
	-1	Amounts related to ratable recognition of upfront fees were $64,000 and $127,000 for the three and six months ended June 30, 2014, respectively, compared to $64,000 and $113,000 for the corresponding periods in 2013.
	-2	Amounts related to recognition of upfront fees were zero and $2.0 million for three months and six months ended June 30, 2014, respectively; the Company and Impax signed a license agreement effective January 3, 2014.
Agreement with Impax Laboratories, Inc. [Member]	'
Summary of Collaborative Research and Development Revenue Recognized	'
	The following table provides a summary of collaborative research and development revenue recognized under the Impax Agreement (in thousands). The cumulative aggregate payments received by the Company as of June 30, 2014 were $2.1 million under the agreement.
			Three months ended				Six months ended
			June 30,				June 30,
			2014		2013		2014		2013
	Ratable recognition of upfront payment		$	—	$	—	$	2,000	$	—
	Research and development expenses reimbursable by Impax			—		—		90		—
	Total collaborative research and development revenue		$	—	$	—	$	2,090	$	—
Agreement with Zogenix, Inc. [Member]	'
Summary of Collaborative Research and Development Revenue Recognized	'
	The following table provides a summary of collaborative research and development revenue recognized under the agreements with Zogenix (in thousands). The cumulative aggregate payments received by the Company as of June 30, 2014 were $12.0 million under these agreements.
			Three months ended				Six months ended
			June 30,				June 30,
			2014		2013		2014		2013
	Ratable recognition of upfront payment		$	64	$	64	$	127	$	113
	Research and development expenses reimbursable by Zogenix			1,319		183		2,037		386
	Total collaborative research and development revenue		$	1,383	$	247	$	2,164	$	499

Financial_Instruments_Tables

Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Summary of Available-for-Sale Securities	'
	The following is a summary of available-for-sale securities as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30, 2014
		Amortized		Unrealized		Unrealized			Estimated
		Cost		Gain		Loss			Fair
									Value
	Money market funds	$	17,284	$	—	$	—		$	17,284
	Certificates of deposit		350		—		—			350
	Commercial paper		500		—		—			500
	Corporate debt		4,840		1		(1	)		4,840
	U.S. Government agencies		13,169		3		(1	)		13,171
		$	36,143	$	4	$	(2	)	$	36,145
	Reported as:
	Cash and cash equivalents	$	17,484	$	—	$	—		$	17,484
	Short-term investments		14,298		2		(1	)		14,299
	Long-term investments		4,011		2		(1	)		4,012
	Long-term restricted investments		350		—		—			350
		$	36,143	$	4	$	(2	)	$	36,145
		December 31, 2013
		Amortized		Unrealized		Unrealized			Estimated
		Cost		Gain		Loss			Fair
									Value
	Money market funds	$	34	$	—	$	—		$	34
	Certificates of deposit		450		—		—			450
	Commercial paper		1,249		—		—			1,249
	Corporate debt		3,257		1		—			3,258
	U.S. Government agencies		16,898		1		(1	)		16,898
		$	21,888	$	2	$	(1	)	$	21,889
	Reported as:
	Cash and cash equivalents	$	5,334	$	—	$	—		$	5,334
	Short-term investments		12,752		2		(1	)		12,753
	Long-term investments		3,352		—		—			3,352
	Long-term restricted investments		450		—		—			450
		$	21,888	$	2	$	(1	)	$	21,889
Summary of Cost and Estimated Fair Value of Available-for-Sale Securities at by Contractual Maturity	'
	The following is a summary of the cost and estimated fair value of available-for-sale securities at June 30, 2014, by contractual maturity (in thousands):
		June 30, 2014
		Amortized		Estimated
		Cost		Fair
				Value
	Mature in one year or less	$	14,848	$	14,849
	Mature after one year through five years		4,011		4,012
		$	18,859	$	18,861

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Stock-Based Compensation Cost that has been Included in Statements of Comprehensive Loss	'
	As of June 30, 2014, the Company has three stock-based compensation plans. The stock-based compensation cost that has been included in the statements of comprehensive loss is shown as below (in thousands):
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Cost of product revenues	$	38		$	43		$	75		$	92
	Research and development		424			501			839			1,071
	Selling, general and administrative		313			307			587			633
	Total stock-based compensation	$	775		$	851		$	1,501		$	1,796
Summary of Assumptions Used to Estimate Fair Value of Options Granted and Shares Purchased	'
	The Company used the following assumptions to estimate the fair value of stock options granted (including fully vested options issued in January 2014 and February 2013) and shares purchased under its employee stock purchase plan for the three and six months ended June 30, 2014 and 2013:
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock options
	Risk-free rate		2.1-2.5	%		1.0-2.5	%		2.0-2.8	%		0.8-2.5	%
	Expected dividend yield		—			—			—			—
	Expected life of option (in years)		6.5-10.0			6.5-9.8			6.5-10.0			5.3-9.8
	Volatility		80-83	%		81-83	%		77-84	%		77-83	%
		Three months ended						Six months ended
		June 30,						June 30,
		2014			2013			2014			2013
	Employee Stock Purchase Plan
	Risk-free rate		0.1	%		0.1	%		0.1	%		0.1-0.2	%
	Expected dividend yield		—			—			—			—
	Expected life of option (in years)		0.5			0.5			0.5			0.5
	Volatility		60	%		64	%		60-81	%		64-69	%

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Schedule of Future Maturities and Interest Payments under Term Loan	'
	Future maturities and interest payments under the term loan as of June 30, 2014, are as follows (in thousands):
	Six months ended December 31, 2014	$	795
	2015		1,590
	2016		8,848
	2017		8,848
	2018		6,023
	Total minimum payments		26,104
	Less amount representing interest		-6,104
	Gross balance of long-term debt		20,000
	Less unamortized debt discount		-214
	Carrying value of long-term debt		19,786
	Less current portion of long-term debt		—
	Long-term debt, less current portion and unamortized debt discount	$	19,786

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		6 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
State of incorporation	'	'	'Delaware	'
Date of incorporation	'	'	6-Feb-98	'
Stock Options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Options to purchase common stock excluded from the denominator in the calculation of diluted net income (loss) per share	20.2	22.2	19.5	21.6

Summary_of_Significant_Account4

Summary of Significant Accounting Policies - Summary of Components of Inventories (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Net [Abstract]	'	'
Raw materials	$2,289	$1,404
Work in process	1,070	1,063
Finished goods	1,195	1,035
Total inventories	$4,554	$3,502

Summary_of_Significant_Account5

Summary of Significant Accounting Policies - Summary of Components of Comprehensive Income (Loss) (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Comprehensive Income Net Of Tax [Abstract]	'	'	'	'
Net loss	($5,478)	($5,145)	($9,078)	($10,328)
Net change in unrealized gain on available-for-sale investments, net of tax	-3	-1	1	-3
Comprehensive loss	($5,481)	($5,146)	($9,077)	($10,331)

Strategic_Agreements_Summary_o

Strategic Agreements - Summary of Collaborative Research and Development and Other Revenues Associated with Company's Major Third-Party Collaborators (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Total collaborative research and development and other revenue	$1,735	$905	$5,247	$1,818
Zogenix, Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Total collaborative research and development and other revenue	1,383	247	2,164	499
Pain Therapeutics, Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Total collaborative research and development and other revenue	246	'	697	1
Pfizer Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Total collaborative research and development and other revenue	73	'	87	13
Impax Laboratories, Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Total collaborative research and development and other revenue	'	'	2,090	'
Others [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Total collaborative research and development and other revenue	$33	$658	$209	$1,305

Strategic_Agreements_Summary_o1

Strategic Agreements - Summary of Collaborative Research and Development and Other Revenues Associated with Company's Major Third-Party Collaborators (Parenthetical) (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Zogenix, Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Amounts related to the ratable recognition of upfront fees	$64,000	$64,000	$127,000	$113,000
Impax Laboratories, Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Amounts related to the ratable recognition of upfront fees	$0	'	$2,000,000	'

Strategic_Agreements_Agreement

Strategic Agreements - Agreement with Impax Laboratories, Inc. - Additional Information (Detail) (Agreement with Impax Laboratories, Inc. [Member], USD $)	0 Months Ended	6 Months Ended
In Millions, unless otherwise specified	Jan. 03, 2014	Jun. 30, 2014	Jan. 03, 2014
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Non-refundable upfront fee	$2	'	'
Future milestone payments	'	'	61
Cumulative aggregate payments received by the Company	'	2.1	'
Development-Based Milestones [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Future milestone payments	31	'	31
Sales-Based Milestones [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Future milestone payments	30	'	30
Revenue recognition milestone achieved	'	$0	'

Strategic_Agreements_Summary_o2

Strategic Agreements - Summary of Collaborative Research and Development Revenue Recognized (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Total collaborative research and development and other revenue	$1,735,000	$905,000	$5,247,000	$1,818,000
Agreement with Impax Laboratories, Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Ratable recognition of upfront payment	'	'	2,000,000	'
Research and development expenses reimbursable by Impax	'	'	90,000	'
Total collaborative research and development and other revenue	0	0	2,090,000	0
Agreement with Zogenix, Inc. [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Ratable recognition of upfront payment	64,000	64,000	127,000	113,000
Research and development expenses reimbursable by Impax	1,319,000	183,000	2,037,000	386,000
Total collaborative research and development and other revenue	$1,383,000	$247,000	$2,164,000	$499,000

Strategic_Agreements_Agreement1

Strategic Agreements - Agreement with Pain Therapeutics, Inc. - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended		139 Months Ended
	Dec. 31, 2002	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
	Drug
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'
Total collaborative research and development and other revenue	'	$1,735,000	$905,000	$5,247,000	$1,818,000	'
Agreement with Pain Therapeutics, Inc. [Member]	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'
Number of specified opioid drugs	4	'	'	'	'	'
Total collaborative research and development and other revenue	'	246,000	0	697,000	1,000	'
Cumulative aggregate payments received by the Company	'	'	'	'	'	35,500,000
Upfront license fee	'	'	'	1,000,000	'	'
Performance milestone payments based on successful development	'	9,300,000	'	9,300,000	'	9,300,000
Agreement with Pfizer [Member]	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'
Total collaborative research and development and other revenue	'	73,000	0	87,000	13,000	'
Cumulative aggregate payments received by the Company	'	'	'	'	'	7,100,000
Development-Based Milestones [Member] | Agreement with Pain Therapeutics, Inc. [Member]	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'
Performance milestone payments based on successful development	'	9,300,000	'	9,300,000	'	9,300,000
Revenue recognition milestone achieved	'	'	'	1,700,000	'	'
Sales-Based Milestones [Member] | Agreement with Pain Therapeutics, Inc. [Member]	'	'	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'	'
Performance milestone payments based on successful development	'	$0	'	$0	'	$0

Strategic_Agreements_Long_Term

Strategic Agreements - Long Term Supply Agreement with King - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Product revenue, net	$2,846,000	$3,013,000	$5,627,000	$6,253,000
Cost of goods sold	1,091,000	1,032,000	2,154,000	2,690,000
Agreement with Pfizer [Member]	'	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'
Product revenue, net	0	0	0	273,000
Cost of goods sold	$0	$0	$0	$219,000

Strategic_Agreements_Agreement2

Strategic Agreements - Agreement with Zogenix, Inc. - Additional Information (Detail) (Agreement with Zogenix, Inc. [Member], USD $)	6 Months Ended	35 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jul. 31, 2011
		Development-Based Milestones [Member]	Sales-Based Milestones [Member]	Up-front Payment Arrangement [Member]	Up-front Payment Arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'	'	'
Non-refundable upfront fee	'	'	'	$2.25	$2.25
Future milestone payments	103	28	75	'	'
Revenue recognition milestone achieved	'	0	0	'	'
Patent royalty term	'15 years	'	'	'	'
Cumulative aggregate payments received by the Company	$12	'	'	'	'

Financial_Instruments_Summary_

Financial Instruments - Summary of Available-for-Sale Securities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$36,143	$21,888
Unrealized Gain	4	2
Unrealized Loss	-2	-1
Estimated Fair Value	36,145	21,889
Money market funds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	17,284	34
Estimated Fair Value	17,284	34
Certificates of deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	350	450
Estimated Fair Value	350	450
Commercial paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	500	1,249
Estimated Fair Value	500	1,249
Corporate debt [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	4,840	3,257
Unrealized Gain	1	1
Unrealized Loss	-1	'
Estimated Fair Value	4,840	3,258
U.S. Government agencies [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	13,169	16,898
Unrealized Gain	3	1
Unrealized Loss	-1	-1
Estimated Fair Value	13,171	16,898
Cash and cash equivalents [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	17,484	5,334
Estimated Fair Value	17,484	5,334
Short-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	14,298	12,752
Unrealized Gain	2	2
Unrealized Loss	-1	-1
Estimated Fair Value	14,299	12,753
Long-term restricted investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	350	450
Estimated Fair Value	350	450
Reported As [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	36,143	21,888
Unrealized Gain	4	2
Unrealized Loss	-2	-1
Estimated Fair Value	36,145	21,889
Long-term investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	4,011	3,352
Unrealized Gain	2	'
Unrealized Loss	-1	'
Estimated Fair Value	$4,012	$3,352

Financial_Instruments_Summary_1

Financial Instruments - Summary of Cost and Estimated Fair Value of Available-for-Sale Securities at by Contractual Maturity (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Investments Debt And Equity Securities [Abstract]	'
Mature in one year or less, Amortized Cost	$14,848
Mature after one year through five years, Amortized Cost	4,011
Amortized Cost	18,859
Mature in one year or less, Estimated Fair Value	14,849
Mature after one year through five years, Estimated Fair Value	4,012
Estimated Fair Value	$18,861

Financial_Instruments_Addition

Financial Instruments - Additional Information (Detail) (USD $)	Jun. 30, 2014
Investments Debt And Equity Securities [Abstract]	'
Unrealized loss of securities	$0

StockBased_Compensation_Summar

Stock-Based Compensation - Summary of Stock-Based Compensation Cost that has been Included in Statements of Comprehensive Loss (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	$775	$851	$1,501	$1,796
Cost of product revenues [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	38	43	75	92
Research and development [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	424	501	839	1,071
Selling, general and administrative [Member]	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Total stock-based compensation	$313	$307	$587	$633

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'
Stock-based compensation cost capitalized in inventory	$14,000	$13,000

StockBased_Compensation_Summar1

Stock-Based Compensation - Summary of Assumptions Used to Estimate Fair Value of Options Granted and Shares Purchased (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free rate, minimum	'	'	'	0.10%
Risk-free rate, maximum	'	'	'	0.20%
Risk-free rate	0.10%	0.10%	0.10%	'
Expected dividend yield	'	'	'	'
Expected life of option (in years)	'6 months	'6 months	'6 months	'6 months
Volatility, minimum	'	'	60.00%	64.00%
Volatility, maximum	'	'	81.00%	69.00%
Volatility	60.00%	64.00%	'	'
Stock Option Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free rate, minimum	2.10%	1.00%	2.00%	0.80%
Risk-free rate, maximum	2.50%	2.50%	2.80%	2.50%
Expected dividend yield	'	'	'	'
Volatility, minimum	80.00%	81.00%	77.00%	77.00%
Volatility, maximum	83.00%	83.00%	84.00%	83.00%
Stock Option Plan [Member] | Minimum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life of option (in years)	'6 years 6 months	'6 years 6 months	'6 years 6 months	'5 years 3 months 18 days
Stock Option Plan [Member] | Maximum [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life of option (in years)	'10 years	'9 years 9 months 18 days	'10 years	'9 years 9 months 18 days

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail) (USD $)	6 Months Ended		3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2014
			Oxford Finance LLC [Member]	Oxford Finance LLC [Member]	Oxford Finance LLC [Member]	Oxford Finance LLC [Member]
					Minimum [Member]	Maximum [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'
Secured term loan	'	'	$20,000,000	$20,000,000	'	'
Term loan, maturity date	'	'	'	1-Jul-18	'	'
Interest rate on term loan	'	'	7.95%	7.95%	'	'
Percentage of an additional payment equal to principal amount	'	'	'	8.00%	'	'
Facility fee paid at final payment	'	'	150,000	150,000	'	'
Percentage of prepayment fee	'	'	'	'	1.00%	3.00%
Term loan repayment description	'	'	'	'The term loan repayment schedule provides for interest only payments for the first 18 months, followed by consecutive equal monthly payments of principal and interest in arrears starting on February 1, 2016	'	'
Proceeds from long term debt, net	19,786,000	0	'	19,786,000	'	'
Debt offering/issuance costs	'	'	'	1,600,000	'	'
Debt instrument, covenants in compliance	'	'	'	'The Company was in compliance with all material covenants under the Loan Agreement and there had been no material adverse change	'	'
Interest expense	'	'	31,000	31,000	'	'
Accrued interest	'	'	$8,000	$8,000	'	'

LongTerm_Debt_Schedule_of_Futu

Long-Term Debt - Schedule of Future Maturities and Interest Payments under Term Loan (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'	'
Six months ended December 31, 2014	$795	'
2015	1,590	'
2016	8,848	'
2017	8,848	'
2018	6,023	'
Total minimum payments	26,104	'
Total minimum payments	26,104	'
Less amount representing interest	-6,104	'
Gross balance of long-term debt	20,000	'
Gross balance of long-term debt	20,000	'
Less unamortized debt discount	-214	'
Carrying value of long-term debt	19,786	'
Less current portion of long-term debt	'	'
Long-term debt, less current portion and unamortized debt discount	$19,786	$0

Subsequent_Event_Additional_In

Subsequent Event - Additional Information (Detail) (USD $)	6 Months Ended				1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2013	Jul. 31, 2014
				Cantor Fitzgerald Co [Member]	Subsequent event [Member]
Subsequent Event [Line Items]	'	'	'	'	'
Securities offered	'	'	$100,900,000	$25,000,000	'
Proceeds from sale of common stock, net of commission	$200,000	$87,000	'	'	$1,600,000
Sale of common stock during period	'	'	'	'	967,057
Common stock weighted average price	'	'	'	'	$1.76